Skin toxicity and effectiveness of first-line enfortumab vedotin plus pembrolizumab for urothelial carcinoma: a prospective multicenter real-world study in Japan

ESMO Real World Data and Digital Oncology · Elsevier

Аннотация

Publication date: December 2026 Source: ESMO Real World Data and Digital Oncology, Volume 14 Author(s): K. Tamura, T. Tsujino, R. Taoka, K. Kobayashi, M. Miyake, K. Ogawa, Y. Sasaki, S. Tatarano, S. Katayama, M. Kato, H. Fukuhara, Y. Abe, Y. Oda, R. Minato, R. Shigehisa, R. Maenosono, M. Sugimoto, K. Shiraishi, K. Fujimoto, K. Wada

Читать у издателя →

Похожие статьи